China's Akeso rises on approval for its first-line cervical cancer treatment

Akeso

05/06/2025 05:19

** Chinese antibody drugs developer Akeso 9926.HK rises ~6% to HK$86, highest since May 30

** Stock on course for third consecutive session of gains

** China's National Medical Products Administration approves supplemental New Drug Application for cadonilimab as first-line treatment for cervical cancer

** Says it is conducting more than 28 clinical trials of combination therapies that include cadonilimab, with indications covering gastric, liver, lung and other types of cancers

** YTD, stock up 36.8%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))